To our knowledge, no reports have been published that evaluate the clinical roles of serum levels of ligands that activate the ErbB family, cMET and IGF-1R pathways on the treatment with trastuzumab in HER2-positive patients with metastatic GC. The gene discussed is EGFR; the disease is gastric cancer.